Navigation Links
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial
Date:1/27/2009

14.3%) for the control arm, p = 0.003). PFS, CR/CRu and ORR were determined by an independent assessment panel that was blinded to the treatment assignments.

The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission or unconfirmed complete remission rate, overall survival and progression-free survival. The study received Special Protocol Assessment approval from the FDA in 2004 and pixantrone has received fast track designation for this indication.

The Company announced on January 27, 2009 that after a pre-NDA communication with the FDA, it expects to begin submission of a rolling NDA and request priority review for pixantrone to treat relapsed aggressive NHL in the first quarter of 2009.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracycl
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. Demand for VScan Dengue Fever Test Kits Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... Thomson CompuMark , the global leader in trademark ... Reuters, today announced the launch of Global Pharmaceutical ... intelligence in a single online report. Avoiding ... to prescription errors, is a critically important public health ...
... Span-America Medical Systems, Inc. (NASDAQ:  SPAN) will provide ... call on Friday, February 3, 2012, covering results for ... after the regular close of trading the preceding day. ... will be available online at www.spanamerica.com under ...
Cached Medicine Technology:Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 2Thomson CompuMark Reduces Drug Approval Delays by Identifying Conflicting Trademarks in International Markets 3
(Date:7/28/2014)... “China Surgical Generators Market Outlook to ... Surgical Generators market. The report provides value, in ... average prices (in US dollars) within market segments ... Argon Plasma Coagulation Generators. , The report also ... each of these market categories, and global corporate-level ...
(Date:7/28/2014)... A January 2013 study published ... in those who were self-diagnosed gluten-intolerant yielded little verifiable ... for San Diego health and wellness retreat VeraVia ... those who are unclear about the role gluten plays ... a protein, found in wheat, barley, rye, and triticale. ...
(Date:7/28/2014)... An estimated 68,000 women and men in the ... cancers – an aggressive form of the disease that ... of the body, such as the lungs, liver, bones, ... of Medicine have developed a compound directed at ... blocking tumor cells from “re-seeding.” Their discovery has been ...
(Date:7/28/2014)... Elementary school students seem to be satisfied with the healthier ... study of school officials. , , New meal standards -- ... effect in the fall of 2012. At the time, there ... away most of their food. But the new study of ... , , "The updated meals standards are resulting in healthier ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... filed on behalf of individuals who were allegedly ... Replacement System continue to move forward in U.S. District ... According to an Order issued on July 18, 2014, ... a motion filed by the Plaintiffs’ Steering Committee that ...
Breaking Medicine News(10 mins):Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Healthy School Lunches Get Thumbs Up From Students 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4
... of therapeutic hypothermia and delay in return of spontaneous ... measurable blood pressure, were both associated with poor neurologic ... study being presented Nov. 14 at the at the ... Also, caregivers who have an appropriate understanding of the ...
... , MONDAY, Nov. 14 (HealthDay News) -- ... greatly increase the risk of Parkinson,s disease, and exposure ... developing the neurodegenerative disorder, a new study indicates. ... have Parkinson,s disease and more than 50,000 new cases ...
... By Denise Mann HealthDay Reporter , SUNDAY, Nov. ... about seemingly healthy young athletes dying on the playing field ... American Heart Association (AHA) issued guidelines aimed at helping doctors ... senseless deaths. But new research suggests that only a ...
... risk, a new study from Washington University School of Medicine ... history of breast disease either cancer or the benign ... of developing benign breast disease as young women than other ... risk rises with increasing alcohol consumption. "The most common ...
... to the increasing evidence that repeated occupational exposure ... Parkinson,s disease. Researchers analyzed the occupational histories of ... the neurodegenerative disorder, and assessed that twin,s likelihood ... Parkinson,s. Of the six chemicals investigated, researchers concluded ...
... 13 (HealthDay News) -- Patients who develop atrial fibrillation ... time while they are hospitalized with severe sepsis are ... study finds. Atrial fibrillation (AF) is one of ... patients, according to background study information. Six percent to ...
Cached Medicine News:Health News:Better understanding of neurologic defects improves post-cardiac-arrest discharge 2Health News:Exposure to Toxic Solvents Linked to Parkinson's Disease 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 3Health News:Girls with family history of breast disease should avoid alcohol 2Health News:Girls with family history of breast disease should avoid alcohol 3Health News:NIH-funded twin study finds occupational chemical exposure may be linked to Parkinson's risk 2Health News:NIH-funded twin study finds occupational chemical exposure may be linked to Parkinson's risk 3Health News:Sepsis Plus Heart Rhythm Disorder Linked to Stroke, Death 2
...
... FLEXILOG antimony pH catheters are designed for patient ... ,All catheters are number marked at 5cm intervals ... than sixteen individual models are available spanning most ... or multi-use models with one or two sensors., ...
... The Standard VersaFlex™ disposable pH ... nurses, and clinics worldwide for evaluating ... catheters for 24-hour esophageal pH monitoring. ... the smallest diameter esophageal catheter on ...
FLEXILOG accessory....
Medicine Products: